Thank you for your interest in our Community!
I suggest that you start by visiting our Disorder Resources section and reading the informative literature highlighted there.
In terms of the likely number of patients, a rough estimate would be one per million, making SCLS one of the rarest of rare diseases. One cannot go by the case-study literature; many of the patients in this Community are not covered by it -- and a number of the early patients described have died.
The impression we have is that in the past few years, most patients with recurring episodes of SCLS have been migrated to an IVIG-focused therapy.
At present, the only scientist performing laboratory studies on SCLS is doing a survey of IVIG users, and based on fewer than 25 patients, virtually all have been able to stop or minimize their episodes.
However, we do not have, and we will probably never have, a proper, double-blind, randomized statistical study of the efficacy of IVIG. This therapy seems to be working so well for patients who have tried everything else without success that it would not be ethical to give any of them a placebo.
For additional information, write to Dr. Kirk Druey, _kdruey@niaid.nih.gov_